Discovery & Characterization of Filo-. Arena -and Alpha Virus Entry Inhibitors
发现
基本信息
- 批准号:7676506
- 负责人:
- 金额:$ 15.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-04-15 至 2010-02-28
- 项目状态:已结题
- 来源:
- 关键词:2-cyclopentyl-5-(5-isoquinolylsulfonyl)-6-nitro-1H-benzo(D)imidazoleAddressAlphavirusAnimal Disease ModelsAnimal ModelAnimalsArenavirusBasic ScienceBiological AssayBiological WarfareCalciumCalcium Channel BlockersCalcium SignalingCategoriesCell CommunicationCellsCercopithecine Herpesvirus 1ChemicalsChikungunya virusClinicCollaborationsDependenceDiseaseDominant-Negative MutationDrug effect disorderEbola Hemorrhagic FeverEbola virusEffectivenessEmerging Communicable DiseasesFDA approvedFamilyFilovirusFrankfurt-Marburg Syndrome VirusGenomicsGoalsInfectionInfection preventionJunin virusLibrariesModelingModificationPathogenesisPathway interactionsPharmaceutical PreparationsPhosphotransferasesPublishingRNA VirusesReportingRoleScreening procedureSeriesSignal TransductionSmall Interfering RNASpecificityStructure-Activity RelationshipSystemTechnologyTestingTherapeuticTherapeutic InterventionTranslatingUnited States National Institutes of HealthVenezuelan Equine Encephalitis VirusVenezuelan Equine EncephalomyelitisViralVirusVirus DiseasesWorkbasebiodefensechikungunyacomparativedensitydosagedrug candidatedrug mechanismenv Gene Productsfollow-upimprovedinhibitor/antagonistmembermouse modelnovel therapeuticsoverexpressionpathogenpreventreceptorrelease of sequestered calcium ion into cytoplasmvirus envelope
项目摘要
RNA viruses are prominent members of NIAID's Category A, B, and C lists of biodefense and emerging
infectious disease agents. In this proposal therapeutics are being identified, characterized and developed.
As our target we have chosen to focus on receptor interaction and entry. This is the first step in establishing
an infection, and disruption has proved effective at preventing infection and virus spread. We have
developed and published a series of assays that have become a platform technology for identifying such
drugs and, importantly, for mechanism of action analysis. Our systems are now developed to the point where
we can perform very high-density screens. To begin, we will use a library of 200,000 compounds in
collaboration with the NIH Chemical Genomics Center. Active compounds will be prioritized based on
comparative analyses of structure-activity relationships across the panel of assays determined from multiple
dosages. Our UTMB team will work to develop hits into useful drugs. We will systematically compare two
members each of three classes of virus, the filoviruses, Ebola and Marburg; arenaviruses, Lassa and Junin;
and the alphaviruses, Venezuelan equine encephalitis and chikungunya viruses. Comparing each virus in
one screen will be an effective means to identify potential drugs active against 1) specific virus types, 2) virus
families, or 3) those of broad spectrum activity. All drugs will be tested against wild-type viruses. Next, we
will follow up on our Ebola virus study, in which we identified FDA-approved drugs effective at blocking Ebola
virus infection. In preliminary screens with small drug libraries and siRNA, we discovered that drugs that
block calcium flux into cells are effective at inhibiting Ebola virus infection and cell entry, thereby preventing
cytopathic effect. We will characterize each drug's mechanism of action. First, we will identify the most
potent calcium channel blocking drugs via our specialized virus entry assays and use of wild-type virus.
Second, we will address mechanism of action by identifying downstream signaling targets (e.g., CALM and
CAM kinases) that may, in turn, be useful targets for anti-viral therapy. Third, we will examine the role of
virus envelope protein in triggering this cascade by biochemically analyzing envelope protein-cell
interactions. Finally, we will test the candidate drugs in animal disease models. We will also test other
filoviruses, including Marburg virus. Our findings will aid in developing a robust filovirus therapy and an
understanding of how calcium signaling functions in virus infection and potentially pathogenesis.
RNA病毒是NIAID A、B和C类生物防御和新兴病毒名单中的重要成员
传染病病原体。在这项提案中,治疗学正在被识别、表征和发展。
作为我们的目标,我们选择专注于受体的相互作用和进入。这是建立
事实证明,破坏是一种感染,在防止感染和病毒传播方面是有效的。我们有
开发并发布了一系列检测方法,已成为鉴定此类疾病的平台技术
药物,更重要的是,用于作用机制分析。我们的系统现在发展到了这样一个地步
我们可以表演非常高密度的银幕。首先,我们将使用一个包含200,000个化合物的库
与美国国立卫生研究院化学基因组中心合作。活性化合物的优先顺序将基于
结构-活性关系的比较分析跨由多个
剂量。我们的UTMB团队将致力于将HITS开发成有用的药物。我们将系统地比较两个
三类病毒的成员,丝状病毒、埃博拉病毒和马尔堡病毒;阿雷纳病毒、拉萨病毒和朱宁病毒;
还有甲型病毒、委内瑞拉马脑炎和基孔肯雅病毒。比较每种病毒在
一次筛查将是识别针对1)特定病毒类型,2)病毒的潜在活性药物的有效手段
家庭,或3)广谱活动的家庭。所有药物都将接受针对野生型病毒的测试。接下来,我们
将跟进我们的埃博拉病毒研究,在该研究中,我们确定了FDA批准的有效阻断埃博拉病毒的药物
病毒感染。在用小的药物文库和siRNA进行初步筛选时,我们发现
阻断钙离子流入细胞可有效抑制埃博拉病毒感染和细胞进入,从而防止
细胞病变效应。我们将描述每种药物的作用机制。首先,我们将确定最多的
通过我们专门的病毒进入试验和使用野生型病毒,有效的钙通道阻断药物。
其次,我们将通过确定下游信令目标(例如,CAMPE和
CaM激酶),这反过来又可能成为抗病毒治疗的有用靶点。第三,我们将研究
通过对包膜蛋白-细胞的生化分析发现病毒包膜蛋白在触发这一级联反应中的作用
互动。最后,我们将在动物疾病模型中测试候选药物。我们还将测试其他
丝状病毒,包括马尔堡病毒。我们的发现将有助于开发一种强大的丝状病毒疗法和
了解钙信号在病毒感染和潜在致病机制中的作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT A DAVEY其他文献
ROBERT A DAVEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT A DAVEY', 18)}}的其他基金
Antiviral Lead Identification to Treat Filovirus Infections
治疗丝状病毒感染的抗病毒先导药物鉴定
- 批准号:
10453443 - 财政年份:2019
- 资助金额:
$ 15.21万 - 项目类别:
Antiviral Lead Identification to Treat Filovirus Infections
治疗丝状病毒感染的抗病毒先导药物鉴定
- 批准号:
10217981 - 财政年份:2019
- 资助金额:
$ 15.21万 - 项目类别:
Antiviral Lead Identification to Treat Filovirus Infections
治疗丝状病毒感染的抗病毒先导药物鉴定
- 批准号:
9765787 - 财政年份:2019
- 资助金额:
$ 15.21万 - 项目类别:
High Biocontainment (BSL4/ABSL4) core for replication competent virus work
用于复制病毒工作的高生物防护 (BSL4/ABSL4) 核心
- 批准号:
10555054 - 财政年份:2016
- 资助金额:
$ 15.21万 - 项目类别:
Roles of host factor protein subnetworks in regulating steps of filovirus infection
宿主因子蛋白亚网在丝状病毒感染调节步骤中的作用
- 批准号:
10555057 - 财政年份:2016
- 资助金额:
$ 15.21万 - 项目类别:
Emerging virus-host cell protein interaction networks
新兴的病毒-宿主细胞蛋白质相互作用网络
- 批准号:
8964885 - 财政年份:2015
- 资助金额:
$ 15.21万 - 项目类别:
Novel broad spectrum inhibitors of filovirus infection
丝状病毒感染的新型广谱抑制剂
- 批准号:
8806955 - 财政年份:2015
- 资助金额:
$ 15.21万 - 项目类别:
Emerging virus-host cell protein interaction networks
新兴的病毒-宿主细胞蛋白质相互作用网络
- 批准号:
9063092 - 财政年份:2015
- 资助金额:
$ 15.21万 - 项目类别:
Novel broad spectrum inhibitors of filovirus infection
丝状病毒感染的新型广谱抑制剂
- 批准号:
9131611 - 财政年份:2015
- 资助金额:
$ 15.21万 - 项目类别:
HTS for Filo- and Arena-virus Entry Mechanisms
用于丝状病毒和沙粒病毒进入机制的 HTS
- 批准号:
7845149 - 财政年份:2009
- 资助金额:
$ 15.21万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 15.21万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 15.21万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 15.21万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 15.21万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 15.21万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 15.21万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 15.21万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 15.21万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 15.21万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 15.21万 - 项目类别:
Research Grant